Navigation Links
Genomics Likely to Replace Traditional Drug Therapies in Treating CHF
Date:4/17/2008

NEW YORK, April 17 /PRNewswire/ -- The market for congestive heart failure (CHF) drug treatments was estimated at $18 billion in 2007, and is expected to reach $30 billion by 2017, according to a new report by Kalorama Information, Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical Management. Growth is being driven by three factors: an increased incidence of CHF, the application of innovative technologies in search of targeted therapies which is creating opportunity for new entrants into this market, and physicians prescribing multi-drug regimens in response to the failure of traditional drugs to treat CHF.

CHF is a complex disorder for which prevention is more effective than treatment, and as part of the larger cardiovascular markets, it is mostly treated with drugs used to treat many other cardiovascular disorders. The lack of targeted treatments means drugs will continue to be applied liberally for prevention and sales will grow disproportionately to the CHF patient population.

"The future of CHF drug treatments lies in newer technologies such as biotechnology and genomics," notes Kenneth Krul, the report's analyst. "The identification of fetal genes associated with CHF, new treatments that address the endothelium and cell therapy to regenerate damaged heart muscle tissue present some promising areas."

The market for drugs to treat CHF will continue to be dominated by major pharmaceutical companies which supply product lines with broad cardiovascular applications. There are, however, many smaller companies focusing primarily on CHF and biotech, and their numbers are growing with the realization that this disease presents a major economic opportunity for which there is currently no adequate answer.

Kalorama Information's report Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical Management focuses on the market potential resulting from the application of current and advanced pharmaceutical and biopharmaceutical technology to the development of CHF treatments in the U.S., France, Germany, Italy, Spain, United Kingdom and Japan, providing forecasts through 2017. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Congestive-Heart-Failure-1399514/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. Kalorama routinely assists media with healthcare topics, and can provide experts to speak about markets in the life sciences industry. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
4. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
5. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
6. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
9. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
10. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, ... ... REGN) today announced that it has joined the Human Vaccines Project, a ... infectious diseases and cancer. , The Human Vaccines Project brings together ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., ... for fast growing biotech companies, announced today the ... Procurement Strategic Advisor. Jim brings nearly 25 years ... and procurement, having spent nearly two decades in ... Chain/Logistics and Procurement at Genzyme and, most recently ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics ... West conference in San Francisco’s Moscone Center from February 16-18, 2016, and at ... , These latest InGaAs PIN diode standard packages feature a TO-46 metal can with ...
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced today that ... Arvados provides capabilities for managing and processing genomic and health data at petabyte ... institutions collecting and analyzing genomic data,” said Adam Berrey chief executive officer at ...
Breaking Biology Technology:
(Date:1/25/2016)... Unisys Corporation (NYSE: UIS ) today announced the implementation ... New York City , to help U.S. ... the United States using passports that are ... of the system at Dulles last year. The system will ... 2016. --> pilot testing of the system at ...
(Date:1/22/2016)... 22, 2016 ... the "Global Biometrics Market in Retail ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ... Biometrics Market in Retail Sector 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):